Cargando…

The effect of sequential therapy for postmenopausal women with osteoporosis: A PRISMA-compliant meta-analysis of randomized controlled trials

BACKGROUND: Osteoporosis, more likely to occur in postmenopausal women, is a chronic condition that usually requires a long-term treatment strategy, but the use of either antiresorptive or anabolic drugs should be limited to 18 to 24 months. Discontinuing antiosteoporosis drugs may result in rapidly...

Descripción completa

Detalles Bibliográficos
Autores principales: Lou, Shenghan, Lv, Houchen, Wang, Guoqi, Li, Zhirui, Li, Ming, Zhang, Licheng, Tang, Peifu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5266008/
https://www.ncbi.nlm.nih.gov/pubmed/27930536
http://dx.doi.org/10.1097/MD.0000000000005496
_version_ 1782500386302590976
author Lou, Shenghan
Lv, Houchen
Wang, Guoqi
Li, Zhirui
Li, Ming
Zhang, Licheng
Tang, Peifu
author_facet Lou, Shenghan
Lv, Houchen
Wang, Guoqi
Li, Zhirui
Li, Ming
Zhang, Licheng
Tang, Peifu
author_sort Lou, Shenghan
collection PubMed
description BACKGROUND: Osteoporosis, more likely to occur in postmenopausal women, is a chronic condition that usually requires a long-term treatment strategy, but the use of either antiresorptive or anabolic drugs should be limited to 18 to 24 months. Discontinuing antiosteoporosis drugs may result in rapidly declining bone mineral density (BMD). Therefore, many patients are treated with the sequential use of 2 or more drugs. However, whether switching treatment from anabolic to antiresorptive drugs or the reverse could maintain or further increase BMD; and whether the sequential therapy could outperform the monotherapy under the same treatment duration still remains unclear. Nowadays, no firm conclusions were drawn. METHODS: We searched Medline, Embase, and Cochrane Library from January 1, 1974 until February 1, 2016 to identify all randomized controlled trials for evaluating the effectiveness of sequential therapy of antiresorptive and anabolic drugs in postmenopausal osteoporosis women with the BMD changes of lumbar spine, femoral neck, and total hip as the outcomes. We evaluated the methodological quality and abstracted relevant data according to the Cochrane Handbook. RESULTS: Eight trials involving 1509 patients were included. The pooled data showed that after switching treatment, the alternative drugs maintained the BMD and significantly increased the percentage change in BMD at the lumbar spine (MD, 3.59; 95% CI, 2.26–4.93), femoral neck (MD, 1.44; 95% CI, 0.60–2.27), and total hip (MD, 1.24; 95% CI, −0.12 to 2.60), although change in BMD was not significantly increased at the total hip. The sequential therapy significantly increased BMD from baseline at the lumbar spine (SMD, 0.59; 95% CI, 0.26–0.91), femoral neck (SMD, 0.22; 95% CI, 0.06–0.37), and total hip (SMD, 0.28; 95% CI, 0.01–0.56). CONCLUSIONS: After switching treatment, sequential therapy further increased BMD. The sequential therapy showed a more significant improvement in BMD compared with any anti-resorptive drug given for the same treatment duration and was as effective as anabolic drugs. Thus, sequential therapy may be recommended as an effective treatment for osteoporotic women. However, more randomized controlled trials are still needed to determine the best sequence and the most appropriate drugs of sequential therapy.
format Online
Article
Text
id pubmed-5266008
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-52660082017-02-06 The effect of sequential therapy for postmenopausal women with osteoporosis: A PRISMA-compliant meta-analysis of randomized controlled trials Lou, Shenghan Lv, Houchen Wang, Guoqi Li, Zhirui Li, Ming Zhang, Licheng Tang, Peifu Medicine (Baltimore) 4200 BACKGROUND: Osteoporosis, more likely to occur in postmenopausal women, is a chronic condition that usually requires a long-term treatment strategy, but the use of either antiresorptive or anabolic drugs should be limited to 18 to 24 months. Discontinuing antiosteoporosis drugs may result in rapidly declining bone mineral density (BMD). Therefore, many patients are treated with the sequential use of 2 or more drugs. However, whether switching treatment from anabolic to antiresorptive drugs or the reverse could maintain or further increase BMD; and whether the sequential therapy could outperform the monotherapy under the same treatment duration still remains unclear. Nowadays, no firm conclusions were drawn. METHODS: We searched Medline, Embase, and Cochrane Library from January 1, 1974 until February 1, 2016 to identify all randomized controlled trials for evaluating the effectiveness of sequential therapy of antiresorptive and anabolic drugs in postmenopausal osteoporosis women with the BMD changes of lumbar spine, femoral neck, and total hip as the outcomes. We evaluated the methodological quality and abstracted relevant data according to the Cochrane Handbook. RESULTS: Eight trials involving 1509 patients were included. The pooled data showed that after switching treatment, the alternative drugs maintained the BMD and significantly increased the percentage change in BMD at the lumbar spine (MD, 3.59; 95% CI, 2.26–4.93), femoral neck (MD, 1.44; 95% CI, 0.60–2.27), and total hip (MD, 1.24; 95% CI, −0.12 to 2.60), although change in BMD was not significantly increased at the total hip. The sequential therapy significantly increased BMD from baseline at the lumbar spine (SMD, 0.59; 95% CI, 0.26–0.91), femoral neck (SMD, 0.22; 95% CI, 0.06–0.37), and total hip (SMD, 0.28; 95% CI, 0.01–0.56). CONCLUSIONS: After switching treatment, sequential therapy further increased BMD. The sequential therapy showed a more significant improvement in BMD compared with any anti-resorptive drug given for the same treatment duration and was as effective as anabolic drugs. Thus, sequential therapy may be recommended as an effective treatment for osteoporotic women. However, more randomized controlled trials are still needed to determine the best sequence and the most appropriate drugs of sequential therapy. Wolters Kluwer Health 2016-12-09 /pmc/articles/PMC5266008/ /pubmed/27930536 http://dx.doi.org/10.1097/MD.0000000000005496 Text en Copyright © 2016 the Author(s). Published by Wolters Kluwer Health, Inc. All rights reserved. http://creativecommons.org/licenses/by-nc-nd/4.0 This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0
spellingShingle 4200
Lou, Shenghan
Lv, Houchen
Wang, Guoqi
Li, Zhirui
Li, Ming
Zhang, Licheng
Tang, Peifu
The effect of sequential therapy for postmenopausal women with osteoporosis: A PRISMA-compliant meta-analysis of randomized controlled trials
title The effect of sequential therapy for postmenopausal women with osteoporosis: A PRISMA-compliant meta-analysis of randomized controlled trials
title_full The effect of sequential therapy for postmenopausal women with osteoporosis: A PRISMA-compliant meta-analysis of randomized controlled trials
title_fullStr The effect of sequential therapy for postmenopausal women with osteoporosis: A PRISMA-compliant meta-analysis of randomized controlled trials
title_full_unstemmed The effect of sequential therapy for postmenopausal women with osteoporosis: A PRISMA-compliant meta-analysis of randomized controlled trials
title_short The effect of sequential therapy for postmenopausal women with osteoporosis: A PRISMA-compliant meta-analysis of randomized controlled trials
title_sort effect of sequential therapy for postmenopausal women with osteoporosis: a prisma-compliant meta-analysis of randomized controlled trials
topic 4200
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5266008/
https://www.ncbi.nlm.nih.gov/pubmed/27930536
http://dx.doi.org/10.1097/MD.0000000000005496
work_keys_str_mv AT loushenghan theeffectofsequentialtherapyforpostmenopausalwomenwithosteoporosisaprismacompliantmetaanalysisofrandomizedcontrolledtrials
AT lvhouchen theeffectofsequentialtherapyforpostmenopausalwomenwithosteoporosisaprismacompliantmetaanalysisofrandomizedcontrolledtrials
AT wangguoqi theeffectofsequentialtherapyforpostmenopausalwomenwithosteoporosisaprismacompliantmetaanalysisofrandomizedcontrolledtrials
AT lizhirui theeffectofsequentialtherapyforpostmenopausalwomenwithosteoporosisaprismacompliantmetaanalysisofrandomizedcontrolledtrials
AT liming theeffectofsequentialtherapyforpostmenopausalwomenwithosteoporosisaprismacompliantmetaanalysisofrandomizedcontrolledtrials
AT zhanglicheng theeffectofsequentialtherapyforpostmenopausalwomenwithosteoporosisaprismacompliantmetaanalysisofrandomizedcontrolledtrials
AT tangpeifu theeffectofsequentialtherapyforpostmenopausalwomenwithosteoporosisaprismacompliantmetaanalysisofrandomizedcontrolledtrials
AT loushenghan effectofsequentialtherapyforpostmenopausalwomenwithosteoporosisaprismacompliantmetaanalysisofrandomizedcontrolledtrials
AT lvhouchen effectofsequentialtherapyforpostmenopausalwomenwithosteoporosisaprismacompliantmetaanalysisofrandomizedcontrolledtrials
AT wangguoqi effectofsequentialtherapyforpostmenopausalwomenwithosteoporosisaprismacompliantmetaanalysisofrandomizedcontrolledtrials
AT lizhirui effectofsequentialtherapyforpostmenopausalwomenwithosteoporosisaprismacompliantmetaanalysisofrandomizedcontrolledtrials
AT liming effectofsequentialtherapyforpostmenopausalwomenwithosteoporosisaprismacompliantmetaanalysisofrandomizedcontrolledtrials
AT zhanglicheng effectofsequentialtherapyforpostmenopausalwomenwithosteoporosisaprismacompliantmetaanalysisofrandomizedcontrolledtrials
AT tangpeifu effectofsequentialtherapyforpostmenopausalwomenwithosteoporosisaprismacompliantmetaanalysisofrandomizedcontrolledtrials